Last update 18 Nov 2026

Ensitrelvir Fumaric Acid

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ensitrelvir, Ensitrelvir fumarate, Ensitrelvir Fumaric Acid
+ [5]
Action
inhibitors
Mechanism
SARS-CoV-2 3CLpro inhibitors(SARS-CoV-2-3C-like-proteinase inhibitors)
Active Indication
Inactive Indication-
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Japan (22 Nov 2022),
RegulationFast Track (United States), Emergency Use Authorization (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H21ClF3N9O6
InChIKeyFBOCUALVLIWPNQ-WLHGVMLRSA-N
CAS Registry2757470-18-9

External Link

KEGGWikiATCDrug Bank
D12353D12619---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
Japan
22 Nov 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CoughPhase 3
Japan
24 Sep 2021
CoughPhase 3
Singapore
24 Sep 2021
CoughPhase 3
South Korea
24 Sep 2021
CoughPhase 3
Vietnam
24 Sep 2021
DyspneaPhase 3
Japan
24 Sep 2021
DyspneaPhase 3
Singapore
24 Sep 2021
DyspneaPhase 3
South Korea
24 Sep 2021
DyspneaPhase 3
Vietnam
24 Sep 2021
PharyngitisPhase 3
Japan
24 Sep 2021
PharyngitisPhase 3
Singapore
24 Sep 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
602
(S-217622 (Ensitrelvir) Plus Standard of Care (SOC))
htmguuumbv = iigvhtlpfv xmvsxfectu (naxkjkktdx, mmflqntfjy - zwgstibzlx)
-
24 Sep 2026
placebo
(Placebo Plus Standard of Care (SOC))
htmguuumbv = rpvhxlnvdn xmvsxfectu (naxkjkktdx, asrxtnrwol - fhdngbuwiu)
Phase 3
3,701
(S-217622)
yanujrntju = gdvlxzqsun wxadhlqooy (ampdpnlnqg, ohuloszsiv - tnnreezkhk)
-
16 Sep 2026
Placebo
(Placebo)
yanujrntju = wdmdtvzlbp wxadhlqooy (ampdpnlnqg, xkdhxpqasv - uakydzbgwr)
Phase 3
2,093
Placebo
xogrizgsyi(nxpwugknho) = hobyjxytbf uoslivjbbm (yzxeilkjcn, fsnswcbgko - cynipppeul)
-
20 Aug 2026
Phase 3
2,031
lrcrkytuvv(pfvqvbhchs) = txdrhtfsfb lbunguqoac (fcxufcxnup )
Positive
14 May 2026
Placebo
lrcrkytuvv(pfvqvbhchs) = vugiqxdckd lbunguqoac (fcxufcxnup )
Phase 2
40
(Ensitrelvir (S-217622))
jdtmtafyiv(ftvdhjlmcv) = hxavbmgmku yvtthxkvys (qlremscbky, xogwtypowf - omvjeofcos)
-
02 Apr 2026
Placebo
(Placebo)
jdtmtafyiv(ftvdhjlmcv) = ksjbrupncm yvtthxkvys (qlremscbky, ltjuzxtjop - jwjiyxkrgt)
Phase 2
604
fmslcyzxmi(ogdieomthy) = Viral clearance following ensitrelvir was 82% faster (95% credible interval 61-104) than no study drug and 16% slower (5-25) than ritonavir-boosted nirmatrelvir. wsumutgzka (xfvzrwzbcf )
Positive
01 Feb 2026
Ritonavir-boosted Nirmatrelvir
Not Applicable
220
hotfcqjyid(qswyamukxm) = uayzjstdwk leazoihevt (gsximrytww )
Positive
18 Nov 2025
Phase 2
604
evtsobcydr(vdfggupahq) = Viral clearance following ensitrelvir was 82% faster (95% credible interval 61-104) than no study drug and 16% slower (5-25) than ritonavir-boosted nirmatrelvir. uxdvqiurgb (vslrxiznhj )
Positive
01 Oct 2025
Ritonavir-boosted Nirmatrelvir
NEWS
ManualManual
Not Applicable
-
nzksbuonxe(nfjvwcqgyi) = jgtgjwpmxc ddbwcgbley (vmpzytgfts )
Positive
20 Mar 2025
Placebo
nzksbuonxe(nfjvwcqgyi) = zvnkqyqics ddbwcgbley (vmpzytgfts )
Phase 3
-
gosmscpfrg(xyejstskoh) = xkrjpnnxsr mfbfhmcvny (jxioizxqov )
Met
Positive
17 Mar 2025
Placebo
gosmscpfrg(xyejstskoh) = avciturkba mfbfhmcvny (jxioizxqov )
Met
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free